George Medicines announced the initiation of two Phase III trials investigating the late-stage drug development company’s proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension.
The FDA found high levels of the same type of carcinogen that led to the recall of some hypertension and heartburn medications in some of the extended-release version metformin drugs that had been tested.
The U.S. Food and Drug Administration approved Allergan’s Durysta (bimatoprost implant) 10 mcg for intracameral administration to treat open-angle glaucoma (OAG) or ocular hypertension.
The Food and Drugs Administration is expanding the regulatory agency’s investigation into impurities in U.S. generic drugs beyond a class of hypertension drugs known as angiotensin II receptor blockers (ARBs).
Privately held Azurity Pharmaceuticals won approval for a liquid form of a hypertension drug for both adult and pediatric patients.
The Trump administration plans to change the way it pays for kidney disease treatments to favor lower cost care at home and transplants over the current standard, dialysis clinics, top health officials said during a press briefing.
Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.
Gelesis announced that the United States Food and Drug Administration cleared the biotechnology company’s lead product candidate Plenity (Gelesis100) as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.
The FDA – looking to ease shortages triggered by several manufacturers recalling the blood pressure medicine valsartan over possible cancer risk – approved a new generic version of the drug.
U.S. health regulators said a third cancer-causing toxin was found in some blood pressure pills recalled by India’s Hetero Labs Ltd., adding to a global recall of commonly used drugs to treat hypertension.